Inmune Bio, Inc.
Inmune Bio, Inc. is a clinical-stage biotechnology company developing immunology-based therapies for inflammatory, neurodegenerative, and rare disease indications. Its pipeline includes CORDStrom and XPro, with the company still pre-commercial and dependent on clinical progress, regulatory milestones, and external financing.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCell therapy program focused on RDEB and related rare disease treatment pathways.
Anti-inflammatory biologic program aimed at neuroinflammation and CNS-related disorders.
Revenue from license agreements, data access arrangements, and related milestones.
Earlier-stage discovery and preclinical work supporting future pipeline expansion.
Customers
The company does not sell broadly to end consumers; its economic customers are patients, physicians, hospitals, and regulators that determine whether its therapies can be adopted and reimbursed. In the near term, value is created through clinical trial enrollment, licensing arrangements, and potential future commercialization of approved biologic products. Academic and hospital partners also matter because they generate clinical data and support development milestones.
Patients with RDEB and other severe unmet-need conditions who would use CORDStrom if approved.
Trial sites that enroll patients, administer study treatment, and generate efficacy/safety data.
FDA, EMA, and MHRA review the company’s CMC, safety, and efficacy packages and determine approval.
Third parties that may fund, license, or commercialize programs or provide clinical data access.
Strategy
The company’s strategy is to advance its lead programs through clinical development, secure regulatory designations, and convert trial data into approval and commercialization opportunities. It is also using collaborations, licensing, and capital raises to fund operations while it remains pre-revenue and cash-consuming. The Mission EB data license and FDA orphan/rare pediatric designations show a focus on de-risking CORDStrom and improving its partnering and approval profile.
Approval would unlock commercialization, exclusivity benefits, and potential PRV value.
Licensing and collaborations can accelerate development and reduce internal spend.
The company has recurring losses and substantial doubt about going concern.
Pipeline breadth can create future value beyond a single asset.
Geography
Inmune Bio is headquartered in the United States, but a meaningful part of its research and development spending occurs in Australia and the United Kingdom. The company also references interactions with U.S., U.K., and European regulators, reflecting a development footprint that is broader than its current revenue base. Foreign currency exposure matters because operating costs are incurred in pounds sterling and Australian dollars while reporting in U.S. dollars.
Risks
Inmune Bio faces classic clinical-stage biotech risks: trial failure, regulatory delay, and uncertainty around whether its programs can reach approval and commercialization. The company also has a going-concern profile, with recurring losses and dependence on equity financing, while foreign-currency exposure and third-party manufacturing/CRO reliance can add volatility to costs and execution.
The company has recurring net losses and negative cash flows and may need additional capital before commercialization.
Exposure: Cash runway and ability to fund clinical development
Pipeline value depends on positive trial outcomes for CORDStrom and XPro.
Exposure: Lead asset approval probability
FDA/EMA/MHRA feedback can require additional studies, manufacturing changes, or delays.
Exposure: Approval timing and development cost
R&D is incurred in Australia and the United Kingdom, creating translation and transaction exposure.
Exposure: Operating expenses and foreign subsidiary balances
Accounting
Judgemental itemsSmall revenue amounts appear tied to a terminated license and prior asset sales, so timing and contract terms matter.
Impact: Can create lumpy quarterly revenue and comparability issues
The company recorded a large impairment charge, indicating valuation sensitivity for development-stage assets.
Impact: Non-cash charge can materially widen reported losses
Equity awards are a recurring compensation tool for a cash-constrained biotech.
Impact: Raises operating expenses and affects loss metrics
R&D spending in pounds sterling and Australian dollars creates exchange-rate effects.
Impact: Moves expenses, assets, and liabilities in reported U.S. dollars
Similar listed companies
Publicly listed companies with a comparable business focus.
IN8bio, Inc
INAB · Biological Products, (No Diagnostic Substances)
Evommune, Inc.
EVMN · Pharmaceutical Preparations
IO Biotech, Inc.
IOBTQ · Pharmaceutical Preparations
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
ImageneBio, Inc.
IMA · Biological Products, (No Diagnostic Substances)
iBio, Inc.
IBIO · Pharmaceutical Preparations
Last updated: 24/09/2026